CTLA4 and cancer: Blocking co-inhibitory checkpoints, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1)/PD-L1, were breakthroughs in the treatment of a variety of malignant tumors [9].